ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The protein degradation start-up Epi- Biologics has launched with $50 million in series A funding. It is targeting cell-surface and extracellular proteins using antibody-based PROTACs, a platform the company calls EpiTAC. EpiBiologics says its atlas of degraders will lead to new treatments for cancer, as well as for immunology and neuro-related conditions. EpiBiologics is based on the work of cofounder Jim Wells, an antibody engineer at the University of California, San Francisco.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X